---
title: "Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286758291.md"
description: "Context Therapeutics has amended its license with BioAtla, agreeing to pay $6.5 million to secure perpetual, royalty-free rights to its antibody licenses, including CT-202. The amendment, effective May 14, 2026, removes R&D obligations and eliminates BioAtla's termination rights, ensuring Context retains full control without future milestone payments or royalties."
datetime: "2026-05-18T10:53:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286758291.md)
  - [en](https://longbridge.com/en/news/286758291.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286758291.md)
---

# Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free

Context Therapeutics entered into a First Amendment to its 2024 license with BioAtla on May 14, 2026. The company will pay $4.5 million within five business days and $2.0 million by August 1, 2026 to convert its licenses, including CT-202, into irrevocable, royalty-free, fully paid-up, non-terminable rights. The amendment removes Context's R&D and certain reporting obligations and eliminates BioAtla's termination rights. BioAtla will no longer receive future milestone payments or royalties for the licensed antibodies.

**Agreement details:**

-   **Agreement type**: First Amendment to License Agreement for antibody assets (including CT-202)
-   **Counterparty**: BioAtla
-   **Signed / Effective**: May 14 2026 / same
-   **Duration / Termination**: Perpetual, non-terminable
-   **Reason**: Eliminate royalties and secure permanent control of licensed assets

Original SEC Filing: Context Therapeutics Inc. \[ CNTX \] - 8-K - May. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BCAB.US](https://longbridge.com/en/quote/BCAB.US.md)
- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)

## Related News & Research

- [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | CNTX Stock News](https://longbridge.com/en/news/286757134.md)
- [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)
- [Heartflow Q1 revenue rises 41% and lifts 2026 outlook](https://longbridge.com/en/news/286460622.md)
- [ChiroTouch Launches CT Pay, Putting Up to $100 a Day Back in Chiropractors' Pockets](https://longbridge.com/en/news/286810158.md)
- [Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | AYTU Stock News](https://longbridge.com/en/news/286813229.md)